The intravenous administration of monocytic myeloid-derived suppressor cells, or M-MDSCs, proved promising in treating rheumatoid arthritis in mice, inhibiting T cell proliferation, as well as B cell proliferation and antibody production.
Amgen wrapped up a second successful Phase III study of its Humira knockoff, ABP501, flagging its head-to-head success in a brief thumb's up announcing that the biosimilar hit its primary and key secondary endpoints. And barring any nasty surprises the positive readout on rheumatoid arthritis should give Amgen the ammunition needed to gun for an approval in a crowded field of late-stage contenders.
The United Kingdom's National Institute for Health Research has teamed up with Johnson & Johnson's Janssen to figure out why anti-TNF drugs are ineffective in some rheumatoid arthritis patients. J&J is funding the collaboration, which is indicative of how the U.K. wants to embed its healthcare infrastructure in drug development.
A new rheumatoid arthritis pill from Eli Lilly and Incyte beat out placebo in a pivotal trial, the first late-stage success for a drug the companies hope can carve out a space in a crowded market.
Johnson & Johnson is walking away from a potential rheumatoid arthritis treatment from Astellas, nixing a deal that could have paid out at $945 million and putting the drug's stateside future in jeopardy.
Johnson & Johnson's plan to grow its pipeline with deal-scouting outposts around the globe is beginning to pay off, as the drugmaker's London lookout has brought in what could be a promising approach to rheumatoid arthritis.
Sanofi is joining forces with UCB to study new small-molecule approaches to treating inflammatory conditions like arthritis, looking for an easier form of administration to some of the blockbuster injected biologics that dominate the field. The pharma giant is ready to spend more than $138 million for a package of milestones and an upfront payment to UCB in exchange for the partnering arrangement with its NewMedicines research arm.
Sanofi has experienced a series of internal setbacks on the R&D front in recent months, but its close partnership with Regeneron is still paying off with promising late-stage data.
Bristol-Myers Squibb's little-discussed rheumatoid arthritis drug clazakizumab posted strong results in a mid-stage study, meeting its endpoints, notching promising remission data and stirring hopes that the treatment can compete with AbbVie's blockbuster Humira.
Isis Pharmaceuticals has opted to throw in the towel on its rheumatoid arthritis program for ISIS-CRP Rx, but the biotech says it will continue to plug away at studies of the antisense treatment for other diseases, including a mid-stage trial for atrial fibrillation due to read out next year.